A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 341 participants.
Also called NCT01256411
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 341 participants
- Sponsor
- Registry
-
NCT01256411
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Japan, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01256411. Allocation not applicable; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2015-10-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Amlodipine
- Intervention (Drug)
- Hydrochlorothiazide (HCTZ)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01256411- Content hash
55aa794582f3b5da60c107581763fe3d623ec88b62b2544ad8ff2898123aacb4